成人糖尿病与非糖尿病患者中漏诊CKD的临床意义
这项全国性人群队列纳入640,217例符合KDIGO实验室标准的CKD成人,56%缺乏电子病历诊断记录;漏诊者虽基线病变较轻,但死亡或KRT风险更高,首年死亡率8.0%对4.1%,SGLT2抑制剂与更好的心肾结局相关但使用率偏低。
要点
- 56%符合KDIGO实验室标准的CKD成人未被诊断。
- 漏诊者首年死亡率8.0%,显著高于已诊断者的4.1%。
- 漏诊者肾脏保护与心脏保护药物使用明显更少。
核心结论
- 真实世界全国CKD队列中漏诊常见,并与过早死亡、肾衰竭和心血管事件相关。
- SGLT2抑制剂与更好的心血管和肾脏结局一致相关。
研究设计与样本
- 全国性、基于人群的队列研究,纳入2000至2023年640,217例符合KDIGO实验室CKD标准的成人。
- CKD漏诊定义为电子病历中无诊断记录,采用多因素Cox比例风险模型并按糖尿病状态分层分析。
主要发现
- 640,217例中359,805例(56%)缺乏CKD诊断记录。
- 漏诊与死亡或KRT时间缩短相关(HR 1.10;95%CI 1.09至1.11)。
- 漏诊者首年死亡率为8.0%(95%CI 7.9至8.1),已诊断者为4.1%(95%CI 4.0至4.2)。
- 漏诊者肾脏保护与心脏保护药物使用显著更少。
- SGLT2抑制剂治疗与死亡、肾衰竭和心血管事件风险降低独立相关,在糖尿病与非糖尿病亚组中一致。
关键数值与推荐
- CKD实验室标准为eGFR<60 ml/min per 1.73 m²和/或UACR>30 mg/g,至少间隔3个月两次达标。
临床怎么用
- 对符合KDIGO实验室标准但无诊断记录者应主动识别并补录CKD诊断。
- 漏诊CKD患者应评估肾脏保护与心脏保护药物(包括SGLT2抑制剂)的使用指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: CKD was undiagnosed in 56% of patients and linked to early mortality, kidney failure, and cardiovascular events despite milder disease. First-year mortality was two-fold higher among undiagnosed patients, emphasizing the short-term risks of missed diagnosis. Sodium-glucose cotransporter 2 inhibitors were associated with better cardiovascular and kidney outcomes, yet their uptake remained low. BACKGROUND: CKD is a global public health challenge, yet underdiagnosis in routine care remains pervasive, leading to missed opportunities for early intervention. Evidence directly linking missed diagnosis to adverse outcomes in large, nationwide populations is limited. METHODS: We conducted a nationwide, population-based cohort study including 640,217 adults meeting Kidney Disease Improving Global Outcomes (KDIGO) laboratory criteria for CKD (eGFR<60 ml/min per 1.73 m 2 and/or urinary albumin-creatinine ratio >30 mg/g on at least two occasions ≥3 months apart) between 2000 and 2023. CKD underdiagnosis was defined as absence of a documented diagnosis in electronic medical records. The primary end point was a composite of all-cause mortality or KRT. Secondary end points included first-year mortality and time to all-cause mortality, KRT, and major cardiovascular events. Associations were assessed using multivariable Cox proportional hazards models, stratified by diabetes status, with additional propensity score-matched sensitivity analyses. RESULTS: Of 640,217 patients who met laboratory criteria for CKD, 359,805 (56%) lacked a documented diagnosis. Undiagnosed patients were younger, more often female, and disproportionately from minoritized populations. Absence of a CKD diagnosis was associated with a markedly shorter time to death or KRT (hazard ratio, 1.10; 95% confidence intervals [CI], 1.09 to 1.11). First-year mortality was higher in undiagnosed versus diagnosed CKD (8.0% [95% CI, 7.9 to 8.1] versus 4.1% [95% CI, 4.0 to 4.2]), despite less advanced disease at baseline. Use of renoprotective and cardioprotective medications was significantly lower in undiagnosed patients. Sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy was independently associated with lower risks of death, kidney failure, and cardiovascular events, showing a consistent protective effect in both diabetic and nondiabetic subgroups. Findings were consistent across sensitivity analyses. CONCLUSIONS: In this real-world nationwide CKD cohort, underdiagnosis was common and associated with premature death, kidney failure, and cardiovascular morbidity. There was consistent association of SGLT2 inhibitors with better cardiovascular and kidney health outcomes.
引用
- Levin-Iaina N, Reiner-Benaim A, Abu-Akel S, et al. Clinical Implications of Missed CKD Diagnosis in Adults with and without Diabetes Mellitus. J Am Soc Nephrol. 2026. PMID: 41563324. doi:10.1681/ASN.0000001005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。